Kornimate/medical-research-clean huggingface dataset:
detection of the uterine abnormalities missed in an ultrasound scan and/or hysterosalpingography using hysteroscopy, in females presenting with unexplained infertility

Conditions: Infertility, Female

Summary: hysteroscopy is still considered the gold standard procedure for uterine cavity exploration. therefore, many specialists have used hysteroscopy as their first-line of routine exam for infertility patients regardless of guidelines. thus, scheduling the office micro hysteroscopy as one of the routine steps in the fertility workup program has become mandatory before the final diagnosis of unexplained infertility.

although hysteroscopy is generally accepted as the gold standard in diagnosis and treatment of uterine cavity pathology, many gynecologist are reluctant to perform hysteroscopy as an initial test without a high degree of suspicion for pathology due to the need for anesthesia in an operating room setting. the basic infertility work-up has included a hsg to evaluate the uterine cavity and tubal patency. however, hsg does not allow for simultaneous correction of uterine pathology. moreover hsg may miss 35% of uterine abnormalities. hysterolaparoscopy (pan endoscopic) approach is better than hsg and should be encouraged as first and final procedure in selected infertile women. sonohysterography (shg) has been proposed as a better diagnostic test of the uterine cavity. however, it also suffers from a sensitivity and specificity inferior to that of hysteroscopy in most studies.

Eligibility criteria:
inclusion criteria: * normal hsg * normal ultrasound * normal hormonal profile * normal semen exclusion criteria: * abnormal findings in different investigations of infertility
quality of life of eye amputated patients in denmark

Conditions: Eye Cancer; Painful Blind Eye; Panophthalmia; Traumas

Summary: the purpose of this study is to evaluate eye amputated patients health related quality of life, perceived stress, self-rated health, labour marked participation and socio-economic position. the investigators hypothesis is that quality of life, perceived stress and self- rated health of many eye amputated patients are drastically changed. eye amputation has a marked negative influence on labour marked participation and socio-economic position of the patients.


Eligibility criteria:
inclusion criteria: * inclusion criteria were operation for evisceration, enucleation, orbital exenteration or secondary implantation of an orbital implant during the period 1996-2003. 267 patients were in 2005 invited to a clinical investigation and of those 173 accepted. * included in this study were patients who came to the clinical investigation, who accepted to receive questionnaires and were alive in 2008. exclusion criteria: * dead * below 18 years * left the country * living at greenland or the faeroe islands
a 12 week safety and efficacy study of sitaxentan sodium in japanese pulmonary arterial hypertension patients

Conditions: Hypertension, Pulmonary

Summary: the safety and efficacy at 100 mg once daily for oral dose of sitaxentan sodium were demonstrated in the stride clinical trial program. sitaxentan sodium was approved in the eu, canada and australia. in this study, the safety and efficacy after administrations of sitaxentan sodium at a dose of 100 mg alone or in combination with another medication will be investigated in japanese pah patients.


Eligibility criteria:
inclusion criteria: * has a current diagnosis of symptomatic pah * has 6mwt distances from 150 to 450 meters and distance exclusion criteria: * previous exposure to an endothelin receptor antagonist * has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure \>160 mm hg or sitting diastolic blood pressure \>100 mm hg at screening. * has hypotension defined as systolic arterial pressure \<90 mm hg after sitting for 5 minutes at screening.

Keywords: sitaxentan sodium hypertension
validation of ipelvis app for female pelvic floor dysfunction

Conditions: Female Sexual Dysfunction; Urinary Incontinence

Summary: the ipelvis app aims to improve adherence to pelvic physiotherapy on women with pelvic floor related dysfunctions, such as urinary or fecal incontinence, sexual dysfunction, etc.

urinary dysfunctions are widely discussed because they cause problems in social, emotional, sexual life and the quality of life of incontinent women. the overall objective of this research is to evaluate the use of the application. ipelvis in women with urinary incontinence. this is a longitudinal study of the type randomized controlled trial. women with urinary incontinence of urgency, effort and effort will be evaluated and treated. frequently asked questions, questions and answers, quality of life questionnaires, health requirements, iciq-sf, iciq-oab, fsfi and evaluation of pelvic, manual and electromyographic floor musculature function. as volunteers are drawn in four groups (group i: household exercise sheet / group ii: ipelvis application / group iii: household exercise sheet + pelvic physiotherapy / group iv ipelvis application + pelvic physiotherapy).

Eligibility criteria:
inclusion criteria: * women with urinary incontinence by urodynamics, stress and mixed urinary incontinence, aged between 18 and 59 years, who have cognitive ability, have a compatible cell to install the ipelvis application and who sign the informed consent form. exclusion criteria: * pregnant women, women up to six months postpartum, women with prolapse greater than stage iii by pelvic organ prolapse - quantification (pop-q), women with urinary tract infection, women with pelvic pain performing therapies offered or having undergone pelvic surgery within a period of less than six months; with a pacemaker or contraceptive device (iud); women with intrapelvic tumor.

Keywords: urinary incontinence female sexual dysfunction quality of life adherence pelvic physiotherapy post-partum
irinotecan plus lobaplatin versus irinotecan in the second-line treatment of small cell lung cancer

Conditions: Small-cell Lung Cancer

Summary: this randomized phase ii study compare survival outcomes and toxicity of two chemotherapy regimens (irinotecan plus lobaplatin or irinotecan) for the second-line treatment of recurrent small-cell lung cancer.

the most widely applied first-line treatment mode for small-cell lung cancer (sclc) patients was chemotherapy as initial treatment. etoposide with cisplatin or carboplatin were considered the standard first-line regimen in sclc. as for second-line chemotherapy, single regimen irinotecan or a combined regimen containing irinotecan were one of preferred regiems. while there still is no consensus on second-line therapy. clinical studies have demonstrated that the combination of irinotecan and carboplatin or cisplatin did not improve outcome in recurrent sclc patients compared with irinotecan alone. one of the main reasons is that carboplatin or cisplatin has been used in the first-line treatment, and sclc showed cross-resistance to carboplatin and cisplatin. lobaplatin is a platinum complex with dna alkylating activity that was developed by asta medica (degussa) for the treatment of cancer. lobaplatin as the third-generation platinum antineoplastic agent, showed promising antineoplastic effects in variety of preclinical test tumor models, which overcomes some forms of cisplatin or carboplatin resistance in preclinical tumour models. retrospective studies also have demonstrated the efficacy of lobaplatin in patients with relapsed sclc. thus, we perform this randomized study to compare the efficacy and safety of irinotecan plus lobaplatin versus irinotecan in patients recurrent sclc.

Eligibility criteria:
inclusion criteria: * relapsed sclc * etoposide with cisplatin or carboplatin was first-line chemotherapy in sclc * at least 30 days after the completion of first-line chemotherapy * either sex, age between 18 to 70 years * expected life time ≥ 3 months * performance status ecog grade 0-1. patients with ps 2 whose general condition is explained by obstructive/bulky disease likely to improve after the first cycle of chemotherapy can be included at the discretion of the local investigator. patients with ps 2 as a result of comorbid conditions will be excluded. * adequate bone marrow and organ function as defined below: neutrophils ≥ 1.5 × 109/l, platelets 80 × 109/l, hemoglobin ≥80 g/l; ast and alt ≤2× the upper limit of the institutional normal range, total bilirubin ≤1.25× the upper limit of the institutional normal range; creatinineconcentration ≤120 μmol/l * had measurable or assessable disease exclusion criteria: * concomitant with other malignant disease * pregnancy or lactation at the time of enrollment * any contraindications for chemotherapy * received target therapy or immunotherapy

Keywords: relapsed
preoperative combined radiation and chemotherapy - rectal cancer

Conditions: Rectal Neoplasms

Summary: there is no established standard preoperative treatment in rectal cancer. two large randomized studies in north america closed from lack of accrual; therefore the only method of assessing preoperative treatment in rectal cancer is from phase ii studies. this study builds on the experience at pmh gained in two previous studies which demonstrated a lower than expected toxicity with concurrent 5fu infusion and external radiotherapy. the current standard at pmh is preoperative radiation, 46gy in 23 fractions with concurrent 5fu infusion 225mg/m2. an increase of radiation dose and consequent increase in chemotherapy may improve the response rate, but may also increase toxicity. it is proposed to increase the dose of radiotherapy to 50gy in 25 fractions with concurrent chemotherapy and measure acute toxicity and complete remission rate.


Eligibility criteria:
inclusion criteria: * biopsy proven adenocarcinoma of the rectum * performance status \<2 (ecog, appendix ii) * clinical stage t2 n1-2, t3-4 no-2, without evidence of distant metastasis exclusion criteria: * prior pelvic irradiation * inflammatory bowel disease * evidence of distant metastasis * performance status \>2
adjuvant chemotherapy based on the adenosine triphosphate tumor chemosensitivity assay for hepatocellular carcinoma after liver transplantation

Conditions: Hepatocellular Carcinoma

Summary: this study is a randomized, open-label, controlled study that will explore the efficacy of individualized adjuvant chemotherapy based on the adenosine triphosphate tumor chemosensitivity assay for patients with hepatocellular carcinoma after liver transplantation.


Eligibility criteria:
inclusion criteria: * patients who had experienced liver transplantation with histologically confirmed advanced hepatocellular carcinoma with more one risk factor (tumour burden \>8 cm, afp\>400 ng/ml,poorly differentiated,vessels invasion ) * no extrahepatic metastasis confirmed with computed tomography (ct) or magnetic resonance imaging (mri) * additional inclusion criteria were age 18 years or older * karnofsky performance status (kps) of at least 70% * adequate renal function, defined as creatinine clearance greater than 30 ml/min) * adequate hepatic function, defined as alt and ast less than 5× upper limit of normal * adequate bone marrow function, defined as platelets greater than 100×10e9/l and wbc greater than 3.5×10e9/l. exclusion criteria: * the presence of any severe concomitant disease that could interrupt the planned treatment; intractable pain * hypersensitivity to study drugs * serious cardiovascular disease (eg, unstable coronary artery disease or myocardial infarction within 4 weeks of study start) * national cancer institute commontoxicity criteria (nci-ctc) grade 3 or 4 sensory or motor neuropathy * prior or concurrent malignancy (other than pancreatic cancer) * female, pregnancy or breastfeeding.
carotid risk prediction (crisp) consortium

Conditions: Carotid Atherosclerosis

Summary: develop adverse event prediction and plaque phenotype classification models for patients with known or suspected carotid artery disease.

develop adverse event prediction and plaque phenotype classification models using plaque morphology and composition assessment of cta which has been validated by histology, applied to representative cohort of patients. generalizability of models is enhanced by using validated rather than only raw image inputs. demographic, clinical, and outcome data is collected for enrolled patients as well as information on events and interventions.

Eligibility criteria:
inclusion criteria: * subjects must have two (or more) neck ctas at least 6 months apart of sufficient quality as documented in the vascucap reading manual. * atherosclerotic plaque must be visualized within the carotid artery. exclusion criteria: * subjects without visible plaque within the carotid artery * subject with insufficient cta image quality (defined strictly as documented in the vascucap reading manual)
the effects of hyperbaric oxygen therapy (hbot) on acute thermal burns

Conditions: Acute Thermal Burns

Summary: the blinded rctstudy aims to: * determine the effects of hbot on burns conversion for patients who have fresh thermal burns injury using the ldi. * objectively determine the proportion of burns conversion in areas of partial thickness burns for early thermal burns injury in both arms of the rct. * study the effects of hbot on immunological markers il-1, il-2, il-4, il-6, il-8, il-10, tnf-α and tgf-β ( comparison between both arms and 2 assessment points). * study the effect of hbot on haematological markers including procalcitonin ,albumin, lymphocyte counts, neutrophil count, and macrophage count. * study the effects of hbot on histology specimens in quantifying p53 protein, leukocyte and macrophage infiltration, burns depth assessment and vascular endothelial growth factor (vegf) and inducible nitric oxide synthase (inos) . * study the effects of hbot on bacteriology of tissue culture in areas of deep dermal burns.


Eligibility criteria:
inclusion criteria: * thermal burns injury less than 40% with areas of deep dermal/ full thickness burns. * less than 24 hours from time of injury. * no inhalational injury (nasoendoscopy and bronchoscopic diagnosis by burns centre medical team/ department of emergency medicine in sgh). * age 21 years old and above and less than 60 years old. * not intubated and not on inotropic support. * understands and agrees to informed consent (approved by irb sgh). exclusion criteria: * untreated pneumothorax * medications: bleomycin, cis-platin, doxorubicin, disulfiram (chemotherapy) * acute uncontrolled medical condition or significant medical condition (eg. cerebrovascular accident, diabetic ketoacidosis, severe hypertensive 180/ 110 mmhg, end stage renal failure, chest pain, bleeding gastrointestinal tract, coma and acute asthma attack) * other surgical emergencies (eg. open fractures, compartment syndrome and acute abdomen)

Keywords: acute thermal burns hyperbaric oxygen therapy burns conversion
generation hd2. a study to evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest huntington's disease

Conditions: Huntington Disease

Summary: this study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest huntington's disease (hd).


Eligibility criteria:
inclusion criteria -hd gene expansion mutation carrier status with a cytosine-adenine-guanine-age product (cap) score of 400-500 inclusive either: * prodromal hd (defined as diagnostic confidence level (dcl) 2 to 3, independence scale (is) ⩾70, and tfc ⩾8); or * early manifest hd (defined as dcl 4, is ⩾70, and tfc ⩾8); * total body weight \> 40 kilograms (kg) and a body mass index (bmi) within the range of 18-32 kilograms per meter square (kg/m2) * study companion exclusion criteria * current or previous use of an antisense oligonucleotide (aso) (including small interfering ribonucleic acid \[rna\]) or any huntingtin gene/protein (htt) lowering therapy (including tominersen) * anti-platelet or anticoagulant therapy within 14 days prior to screening or anticipated use during the study, including, but not limited to, aspirin (unless ≤ 81 milligrams per day \[mg/day\]), clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban, apixaban, and heparin * history of gene therapy, cell transplantation, or brain surgery * hydrocephalus * pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 5 months after the final dose of study drug * history of attempted suicide or suicidal ideation with plan (i.e., active suicidal ideation) that required hospital visit and/or change in level of care within 12 months prior to screening

Keywords: prodromal and early manifest huntington's disease
evaluation of time interval between ovulation trigger with triptorelin acetate and oocyte retrieval

Conditions: Female Urogenital Diseases

Summary: the aim of this study is to determine what is the best time interval between gnrh agonist (triptorelin acetate) ovulation induction allowing for the higher number of mature oocytes (mii) collected in ivf cycles.

human chorionic gonadotrophin (hcg) has been the gold standard for ovulation induction for several decades. when gnrh antagonist protocols were introduced, it became possible to trigger final oocyte maturation and ovulation with a single bolus of a gnrh agonist (gnrha) as an alternative to hcg. the use of gnrha to trigger final oocyte maturation has potential advantages: the simultaneous induction of a fsh surge, higher numbers of mature oocytes retrieved as compared to hcg and the total elimination of ovarian hyperstimulation syndrome. from the earliest reports of gnrha for ovulation triggering, it has been presumed that the timing of the ovum pick-up (opu) after gnrha administration should be the same as after hcg triggering (34-36 h). however, differences exist regarding the duration and profile of the gnrha induced surge of gonadotrophins when compared with that of hcg. even more, differences in the intra-follicular mechanisms involved in ovulation have been described after gnrha and hcg trigger. no previous randomized controlled trials have been reported to evaluate the optimal interval of time between ovulation induction by gnrha and oocyte collection. the present study compares the ovarian response and the ivf outcomes after induction by triptorelin 0.2 mg at four different time intervals: group 1: opu 24 hours after gnrha administration. group 2: opu 30 hours after gnrha administration. group 3: opu 40 hours after gnrha administration. group 4: control group: opu 36 hours after gnrha administration.

Eligibility criteria:
inclusion criteria: * signed informed consent prior to carry out any procedure associated with the clinical trial. * women between 18 and 37 years of age at the time of randomization (both ages included). basal serum levels of fsh \<10 miu /ml. * serum amh \> 5 to \<45 pmol / l. * antral follicle count \> 6 and \< 24. * vaginal ultrasound documenting correct visualization of both ovaries and the absence of significant ovarian pathology. * short stimulation protocol with gnrh antagonist and conventional dose for ovarian stimulation with 225-300 ui of rhfsh. * number of follicles ≥ 16 mm \> 5 on the ovulation induction day. exclusion criteria: * presence of severe endometriosis (grade iii-iv). * absence of one ovary due to previous surgery. * presence of significant uterine pathology (submucous myomas, endometrial polyp, malformations..) * diagnosis of polycystic ovary syndrome (defined according to the rotterdam criteria). * history of previous poor response to conventional ovarian stimulation protocols (\< 3 mii oocytes or canceled cycle) * severe male factor ( tms\< 1 million). * participation in another rct within the past one year.

Keywords: ovulation induction,oocyte maturation timing and collection
a study of recombinant vaccinia virus prior to sorafenib to treat unresectable primary hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: the purpose of this pilot safety study is to evaluate the safety and tolerability of jx-594 (pexa-vec) administered intravenously and intratumorally prior to standard sorafenib therapy.


Eligibility criteria:
inclusion criteria: * histological confirmation or clinical/laboratory diagnosis of primary hepatocellular carcinoma (hcc) * cancer is not surgically resectable for cure * child pugh a or b * performance score: kps score of ≥ 70 * platelet count ≥ 50,000 plts/mm3 * total bilirubin ≤ 2.5 x uln * ast, alt \< 5.0 x uln * acceptable coagulation status: inr ≤ 1.5 x uln * acceptable kidney function: serum creatinine \< 2.0 mg/dl * sorafenib naive or refractory to sorafenib therapy tumor status: at least one intrahepatic tumor, and at least ≥50% of the total intrahepatic viable tumor mass, measurable by ct and injectable under imaging-guidance (note: injected and/or viable tumors must be previously untreated or ≥20% increase in size since preceding local-regional treatment). exclusion criteria: * known contraindications to sorafenib * pregnant or nursing an infant * significant immunodeficiency due to underlying illness (e.g. hematological malignancies, congenital immunodeficiencies and/or hiv infection/aids) and/or medication (e.g. high-dose systemic corticosteroids) * history of exfoliative skin condition (e.g. severe eczema, ectopic dermatitis, or similar skin disorder) that at some stage has required systemic therapy * clinically significant and/or rapidly accumulating ascites, peri-cardial and/or pleural effusions * severe or unstable cardiac disease * current, known cns malignancy * use of anti-platelet or anti-coagulation medication * use of the following anti-viral agents: ribavirin, adefovir, cidofovir (within 7 days prior to the first treatment), and peg-ifn (within 14 days prior to the first treatment). * patients with household contacts who meet any of these criteria unless alternate living arrangements can be made during the patient's active dosing period and for 7 days following the last dose of study medication: * pregnant or nursing an infant * children \< 12 months old * history of exfoliative skin condition that at some stage has required systemic therapy * significant immunodeficiency due to underlying illness (e.g. hiv/aids) and/or medication

Keywords: vaccinia vaccinia virus jx-594 jennerex primary hepatocellular carcinoma primary liver cancer liver cancer sorafenib nexavar pexa-vec